Company Description
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures.
It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation.
The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors.
The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017.
InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Country | Israel |
Founded | 2008 |
IPO Date | Aug 8, 2019 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 599 |
CEO | Moshe Mizrahy |
Contact Details
Address: Tavor Building, Sha’ar Yokneam Yokne'am, 2069206 Israel | |
Phone | 972 4 909 6313 |
Website | inmodemd.com |
Stock Details
Ticker Symbol | INMD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $14.00 |
CIK Code | 0001742692 |
CUSIP Number | M5425M103 |
ISIN Number | IL0011595993 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Moshe Mizrahy | Chief Executive Officer and Director |
Yair Malca | Chief Financial Officer |
Alon Yaari | Vice President of Operations |
Dr. Michael Kreindel | Chief Technology Officer and Director |
Nava Tal-Launer | Chief Information Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 6, 2025 | 6-K/A | Filing |
Feb 4, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 4, 2025 | 20-F | Annual and transition report of foreign private issuers |
Feb 4, 2025 | 6-K | Report of foreign issuer |
Jan 16, 2025 | SCHEDULE 13D | Filing |
Oct 30, 2024 | 6-K | Report of foreign issuer |
Oct 16, 2024 | UPLOAD | Filing |
Oct 1, 2024 | 6-K | Report of foreign issuer |
Sep 30, 2024 | UPLOAD | Filing |
Sep 10, 2024 | UPLOAD | Filing |